Prevail Therapeutics Inc. (PRVL) is a publicly traded company in the Unknown sector. Across all available filings, 9 corporate insiders have executed 19 transactions totaling $816.4M, demonstrating a bullish sentiment with $816.4M in net insider flow. The most recent transaction on Jan 22, 2021 involved a purchase of 34,284,789 shares valued at $771.4M.
No significant insider buying has been recorded for PRVL in the recent period.
No significant insider selling has been recorded for PRVL in the recent period.
Based on recent SEC filings, insider sentiment for PRVL is bullish with an Insider Alignment Score of 100/100 and a net flow of $816.4M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Prevail Therapeutics Inc. (PRVL) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 9 insiders are actively trading PRVL stock, having executed 19 transactions in the past 90 days. The most active insider is Acquisition Corp Tyto (Executive), who has made 1 transactions totaling $771.4M.
Get notified when executives and directors at PRVL file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jan 22, 2021 | Corp Tyto Acquisition | Executive | Purchase | 34,284,789 | $22.50 | $771.4M | Large |
| Jan 22, 2021 | A. Thompson Peter | Executive | Tender | 13,822,463 | $N/A | $0 | |
| Jan 22, 2021 | L. Gordon Carl | Executive | Tender | 13,822,463 | $N/A | $0 | |
| Jan 22, 2021 | Nussbaum Ran | Executive | Tender | 1,576,881 | $N/A | $0 | |
| Jan 22, 2021 | Nader Francois | Executive | Tender | 23,747 | $N/A | $0 | |
| Jan 22, 2021 | Minkow Emily | Executive | Tender | 13,000 | $N/A | $0 | |
| Jan 22, 2021 | Abeliovich Asa | Executive | Tender | 2,385,756 | $N/A | $0 | |
| Jan 22, 2021 | Gp VI Llc Orbimed Capital | Executive | Tender | 13,822,463 | $N/A | $0 | |
| Dec 30, 2020 | Abeliovich Asa | Executive | Option Exercise | 5,256 | $0.18 | $946 | |
| Dec 30, 2020 | Abeliovich Asa | Executive | Option Exercise | 120,537 | $10.26 | $1.2M | Large |
| Dec 30, 2020 | Abeliovich Asa | Executive | Payment | 89,037 | $23.02 | $2.0M | Large |
| Dec 24, 2019 | Minkow Emily | Executive | Option Exercise | 13,000 | $0.18 | $2.3K | |
| Jun 24, 2019 | Nader Francois | Executive | Conversion | 23,747 | $N/A | $0 | |
| Jun 24, 2019 | Llc Orbimed Advisors | Executive | Conversion | 10,510,111 | $N/A | $0 | |
| Jun 24, 2019 | Llc Orbimed Advisors | Executive | Purchase | 882,352 | $17.00 | $15.0M | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 4 | $816.4M | 99.6% |
Payment(F) | 1 | $2.0M | 0.3% |
Exercise(M) | 3 | $1.2M | 0.2% |
Tender(U) | 7 | $0 | 0.0% |
Conversion(C) | 4 | $0 | 0.0% |
Insiders at Prevail Therapeutics Inc. are accumulating shares at an accelerated pace. With 9 insiders making 19 transactions totaling $816.4M in purchases versus $0 in sales, the net buying activity of $816.4M signals strong executive confidence. Acquisition Corp Tyto (Executive) leads the buying activity with $771.4M in transactions across all time.